Interleukin-1 and Tumor Necrosis Factor-Alpha: Novel Targets for Immunotherapy in Eales Disease

Abstract

Raised levels of IL-1beta and TNF-alpha were observed in the inflammatory stage and persisted in the proliferative stage of the disease. The IL-1 system and TNF-alpha represent novel target for immunotherapy for controlling inflammatory activity and/or the associated long-term sequelae related to angiogenesis in Eales disease.